Answers are grounded in this paper and cite their sources.
Review evaluates stem cell therapy and scaffold delivery systems for cardiac regeneration after myocardial infarction, highlighting challenges in cell retention and clinical translation.
It is estimated that by 2030, almost 23.6 million people will perish from cardiovascular disease, according to the WHO. The review discusses advances in stem cell therapy for myocardial infarction, including cell sources, methods of differentiation, expansion selection and their route of delivery. Skeletal muscle cells, hematopoietic cells and mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs)-derived cardiomyocytes have advanced to the clinical stage, while induced pluripotent cells (iPSCs) are yet to be considered clinically. Delivery of cells to the sites of injury and their subsequent retention is a major issue. The development of supportive scaffold matrices to facilitate stem cell retention and differentiation are analyzed. The review outlines clinical translation of conjugate stem cell-based cellular therapeutics post-myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: